Piperacillin/Tazobactam Versus ceftriAxone and Metronidazole for Children With Perforated Appendicitis (ALPACA)
Launched by MCMASTER CHILDREN'S HOSPITAL · Jul 4, 2023
Trial Information
Current as of July 01, 2025
Not yet recruiting
Keywords
ClinConnect Summary
The ALPACA trial is a study that aims to find out which antibiotic treatment is more effective for children who have undergone surgery for a specific type of appendicitis called perforated appendicitis. In this condition, the appendix has a hole in it, which can lead to infection. The trial will compare two different antibiotics: piperacillin/tazobactam and a combination of ceftriaxone and metronidazole. This initial study will help researchers determine if it is feasible to conduct a larger trial in multiple centers.
To be eligible for this study, children must be undergoing a laparoscopic appendectomy (a type of minimally invasive surgery) and have a confirmed perforated appendicitis during the surgery. Unfortunately, children who have certain conditions, like those with non-perforated appendicitis or allergies to specific antibiotics, cannot participate. The trial is not yet recruiting participants, but once it starts, families can expect to learn more about the antibiotic treatment options for their child following surgery, helping to improve care for future patients.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Laparoscopic appendectomy
- • Perforated appendicitis confirmed intra-operatively (i.e., visible hole in appendix, fecalith found in peritoneal cavity, intra-abdominal abscess, and/or purulent fluid in peritoneal cavity)
- Exclusion Criteria:
- • Non-operative treatment (e.g., due to abscess)
- • Interval laparoscopic appendectomy
- • Conversion to open procedure
- • Non-perforated appendicitis
- • Confirmed or suspected allergy to penicillins or cephalosporins
- • Renal impairment
About Mcmaster Children's Hospital
McMaster Children’s Hospital is a leading pediatric healthcare institution dedicated to advancing child health through innovative research and clinical excellence. As a prominent sponsor of clinical trials, the hospital focuses on improving treatments and outcomes for children with various medical conditions. Leveraging its multidisciplinary expertise and state-of-the-art facilities, McMaster Children’s Hospital collaborates with academic institutions, healthcare providers, and industry partners to conduct rigorous clinical research that adheres to the highest ethical standards. Committed to fostering a culture of inquiry and discovery, the hospital aims to translate research findings into practical applications that enhance the quality of care for pediatric patients.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Michael H Livingston, MD, MSc
Principal Investigator
McMaster Children's Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported